Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer
- PMID: 11824881
- DOI: 10.1053/clon.2001.9308
Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer
Abstract
Certain side-effects of chemotherapy are well recognized but ocular toxicity is often underestimated. This retrospective study was undertaken after we became aware of a case of irreversible lacrimal duct stenosis in a woman receiving adjuvant chemotherapy for early stage breast cancer. Using the chemotherapy records, 128 patients who received adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer over a 2 1/2-year period were identified. The case notes of these patients were reviewed and an 18% incidence of ocular side-effects, including four other cases of epiphora, was identified. The epiphora resolved fully on completion of chemotherapy in these four patients but not in the index patient. The optimal management of these side-effects is unclear but it needs to be tailored to the particular toxicity experienced by the patient.
Similar articles
-
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.Cancer. 2003 Jan 1;97(1):21-9. doi: 10.1002/cncr.10982. Cancer. 2003. PMID: 12491501 Clinical Trial.
-
Adjuvant chemotherapy in breast cancer: back to the future.Onkologie. 2003 Apr;26(2):111-2. doi: 10.1159/000071509. Onkologie. 2003. PMID: 12771517 No abstract available.
-
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.J Clin Oncol. 2002 Dec 15;20(24):4628-35. doi: 10.1200/JCO.2002.05.042. J Clin Oncol. 2002. PMID: 12488406
-
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.Lancet Oncol. 2005 Nov;6(11):886-98. doi: 10.1016/S1470-2045(05)70424-1. Lancet Oncol. 2005. PMID: 16257797 Review.
-
Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature.Doc Ophthalmol. 1995;90(1):1-6. doi: 10.1007/BF01203288. Doc Ophthalmol. 1995. PMID: 8549238 Review.
Cited by
-
Ocular toxicity of systemic anticancer chemotherapy.Pharm Pract (Granada). 2006 Apr;4(2):55-9. Pharm Pract (Granada). 2006. PMID: 25247000 Free PMC article. Review.
-
Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.J Clin Pharm Ther. 2010 Jun;35(3):249-55. doi: 10.1111/j.1365-2710.2009.01086.x. J Clin Pharm Ther. 2010. PMID: 20831527 Free PMC article.
-
Ocular adverse effects of anti-cancer chemotherapy.J Med Life. 2023 Jun;16(6):818-821. doi: 10.25122/jml-2023-0041. J Med Life. 2023. PMID: 37675170 Free PMC article. Review.
-
Ocular side effects of antirheumatic medications: a qualitative review.BMJ Open Ophthalmol. 2020 Jan 7;5(1):e000331. doi: 10.1136/bmjophth-2019-000331. eCollection 2020. BMJ Open Ophthalmol. 2020. PMID: 32154367 Free PMC article. Review.
-
Identifying causal relationships of cancer treatment and long-term health effects among 5-year survivors of childhood cancer in Southern Sweden.Commun Med (Lond). 2022 Mar 2;2:21. doi: 10.1038/s43856-022-00081-z. eCollection 2022. Commun Med (Lond). 2022. PMID: 35603279 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical